CO5611152A2 - Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen - Google Patents
Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienenInfo
- Publication number
- CO5611152A2 CO5611152A2 CO04076757A CO04076757A CO5611152A2 CO 5611152 A2 CO5611152 A2 CO 5611152A2 CO 04076757 A CO04076757 A CO 04076757A CO 04076757 A CO04076757 A CO 04076757A CO 5611152 A2 CO5611152 A2 CO 5611152A2
- Authority
- CO
- Colombia
- Prior art keywords
- receiver
- hydrogen
- tachycine
- antigonists
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1.- Un compuesto de fórmula (I) R representa halógeno o alquilo de C1-4; R1 representa alquilo de C1-4; R2 o R3 representan de manera independiente hidrógeno o alquilo de C1-4; R4 representa trifluorometilo, alquilo de C1-4, alcoxi de C1-4, trifluorometoxi o halógeno; R5 representa hidrógeno, alquilo de C1-4 o cicloalquilo de C3-7; R6 es hidrógeno y R7 es un radical de fórmula (W): o R6 es un radical de fórmula (W) y R7 es hidrógeno; X representa CH2, NR5 u O; Y representa nitrógeno y Z es CH o Y representa CH y Z es nitrógeno; A representa C(O) o S(O)q, con la condición de que cuando Y es nitrógeno y Z es CH, A no es S(O)q; m es cero o un número entero de 1 a 3; n es un número entero de 1 a 3; p y q son de manera independiente un número entero de 1 a 2; y sales y solvatos farmacéuticamente aceptables de los mismos.2.- El compuesto de conformidad con la reivindicación 1, caracterizado además porque R6 es hidrógeno, R7 es un radical de fórmula (W) e Y es CH y Z es nitrógeno o en donde R6 es un radical de fórmula (W), R7 es un hidrógeno e y es nitrógeno y Z es CH.3.- El compuesto de conformidad con la reivindicación 1 o la reivindicación 2, caracterizado además porque A es C(O).4.- El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 3, caracterizado además porque X es CH2.5.- El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 3, caracterizado además porque p es 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0203020.3A GB0203020D0 (en) | 2002-02-08 | 2002-02-08 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5611152A2 true CO5611152A2 (es) | 2006-02-28 |
Family
ID=9930717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO04076757A CO5611152A2 (es) | 2002-02-08 | 2004-08-06 | Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen |
Country Status (27)
Country | Link |
---|---|
US (3) | US7189713B2 (es) |
EP (2) | EP1666465B1 (es) |
JP (1) | JP4488743B2 (es) |
KR (1) | KR101011316B1 (es) |
CN (1) | CN1319973C (es) |
AR (1) | AR038818A1 (es) |
AT (2) | ATE308543T1 (es) |
AU (1) | AU2003205753B9 (es) |
BR (1) | BRPI0307123B8 (es) |
CA (1) | CA2475619C (es) |
CO (1) | CO5611152A2 (es) |
DE (2) | DE60302137T2 (es) |
DK (1) | DK1472256T3 (es) |
ES (2) | ES2250870T3 (es) |
GB (1) | GB0203020D0 (es) |
HK (1) | HK1072251A1 (es) |
IL (2) | IL162765A0 (es) |
IS (1) | IS2402B (es) |
MX (1) | MXPA04006791A (es) |
MY (1) | MY130411A (es) |
NO (1) | NO329379B1 (es) |
NZ (1) | NZ533785A (es) |
PL (1) | PL211082B1 (es) |
RU (1) | RU2336276C2 (es) |
TW (1) | TWI291466B (es) |
WO (1) | WO2003066635A1 (es) |
ZA (1) | ZA200404842B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
TWI283241B (en) | 2002-05-29 | 2007-07-01 | Tanabe Seiyaku Co | Novel piperidine compound |
EP1594574A2 (en) * | 2003-01-27 | 2005-11-16 | Glaxo Group Limited | Nk1 receptor antagonists for the treatment of functional dyspepsia |
GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
US8604200B2 (en) * | 2005-03-08 | 2013-12-10 | Janssen Pharmaceutica N.V. | Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists |
WO2007028654A1 (en) | 2005-09-09 | 2007-03-15 | Smithkline Beecham Corporation | Pyridine derivatives and their use in the treatment of psychotic disorders |
AR057828A1 (es) | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
WO2007081897A2 (en) * | 2006-01-11 | 2007-07-19 | Merck & Co., Inc. | Fused triazole tachykinin receptor antagonists |
US7872022B2 (en) * | 2006-04-03 | 2011-01-18 | Hoffmann-La Roche Inc. | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety |
GB0621229D0 (en) * | 2006-10-20 | 2006-12-06 | Glaxo Group Ltd | Novel use |
EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
WO2009002770A1 (en) * | 2007-06-22 | 2008-12-31 | Merck & Co., Inc. | 6.5-pyrrolopiperidine tachykinin receptor antagonists |
GB0806652D0 (en) | 2008-04-11 | 2008-05-14 | Glaxo Group Ltd | Anhydrous crystal form of orvepitant maleate |
GB0812849D0 (en) * | 2008-07-14 | 2008-08-20 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
GB0814340D0 (en) | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
NO2729147T3 (es) | 2011-07-04 | 2018-02-03 | ||
AU2013224181A1 (en) * | 2012-02-22 | 2014-10-02 | Leo Pharma A/S | Novel neurokinin 1 receptor antagonist compounds |
LT2906219T (lt) * | 2012-10-11 | 2019-10-25 | Nerre Therapeutics Ltd | Orvepitantas, skirtas lėtinio niežulio gydymui |
CN105579456A (zh) * | 2013-08-20 | 2016-05-11 | 利奥制药有限公司 | 新型神经激肽1受体拮抗剂化合物ii |
WO2015024203A1 (en) * | 2013-08-20 | 2015-02-26 | Leo Pharma A/S | Novel neurokinin 1 receptor antagonist compounds ii |
PL3377064T3 (pl) * | 2016-01-08 | 2020-02-28 | Nerre Therapeutics Limited | Orwepitant do leczenia przewlekłego kaszlu |
EA201992414A1 (ru) | 2017-04-10 | 2020-03-16 | Чейс Терапьютикс Корпорейшн | Комбинация nk1-антагониста и способ лечения синуклеинопатий |
MA49524A (fr) | 2017-06-30 | 2021-05-26 | Chase Therapeutics Corp | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression |
KR20220165251A (ko) | 2020-04-03 | 2022-12-14 | 네르 쎄라퓨틱스 리미티드 | 패혈증, 패혈성 쇼크, 급성 호흡 곤란 증후군 (ards) 또는 다발성 기관 기능장애 증후군 (mods)으로부터 선택된 질환을 치료하기 위한 nk-1 수용체 길항제 |
US11872222B2 (en) | 2020-06-02 | 2024-01-16 | Nerre Therapeutics Limited | Uses |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL47168A (en) | 1974-05-09 | 1979-07-25 | Toyama Chemical Co Ltd | Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same |
US4327097A (en) | 1974-05-09 | 1982-04-27 | Toyama Chemical Co., Ltd. | Novel penicillins |
US4087424A (en) | 1974-05-09 | 1978-05-02 | Toyama Chemical Co., Ltd. | Novel penicillins and cephalosporins and process for producing the same |
US4410522A (en) | 1974-05-09 | 1983-10-18 | Toyama Chemical Co., Ltd. | Cephalosporins |
US4219554A (en) | 1974-05-09 | 1980-08-26 | Toyama Chemical Company, Limited | Novel penicillins and cephalosporins and process for producing same |
US4112090A (en) | 1974-05-09 | 1978-09-05 | Toyama Chemical Co., Ltd. | Novel penicillins and cephalosporins and process for producing the same |
US4379152A (en) | 1974-05-09 | 1983-04-05 | Toyama Chemical Co., Ltd. | Cephalosporins |
US4110327A (en) | 1974-05-09 | 1978-08-29 | Toyama Chemical Co., Ltd. | 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives |
NO154582C (no) | 1978-10-20 | 1986-11-05 | Ferrosan Ab | Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider. |
JPS57118587A (en) | 1981-11-26 | 1982-07-23 | Toyama Chem Co Ltd | Novel penicillin |
KR910009880B1 (ko) | 1983-07-25 | 1991-12-03 | 가부시기가이샤 히다찌세이사꾸쇼 | 인터레이스된 텔레비젼 신호중의 화상의 움직임 검출회로 |
US5028610A (en) | 1987-03-18 | 1991-07-02 | Sankyo Company Limited | N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use |
GB8709666D0 (en) | 1987-04-23 | 1987-05-28 | Beecham Group Plc | Compounds |
GB8713061D0 (en) | 1987-06-04 | 1987-07-08 | Beecham Group Plc | Compounds |
US5109014A (en) | 1990-12-10 | 1992-04-28 | Jacobson Richard M | N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides |
GB9106127D0 (en) | 1991-03-22 | 1991-05-08 | Byrne Charles M | Spread |
SE9100860D0 (sv) | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
DK0533280T4 (da) | 1991-09-20 | 2005-02-28 | Glaxo Group Ltd | Ny medicinsk anvendelse af tachykininantagonister |
CA2083891A1 (en) | 1991-12-03 | 1993-06-04 | Angus Murray Macleod | Heterocyclic compounds, compositions containing them and their use in therapy |
US5563127A (en) | 1993-03-24 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Boronic acid and ester inhibitors of thrombin |
US5348955A (en) | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
IL111730A (en) | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
DE4425146A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
RU2156763C2 (ru) | 1994-07-15 | 2000-09-27 | Мейдзи Сейка Кабусики Кайся | Азотсодержащие гетероциклические производные, фармацевтическая композиция на их основе и способ лечения или профилактики тромботических заболеваний |
AU3085895A (en) | 1994-07-26 | 1996-02-22 | Sankyo Company Limited | N-phenylated amide and urea derivatives |
DE19520499C2 (de) | 1994-09-17 | 2003-06-18 | Boehringer Ingelheim Kg | Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung |
US5696123A (en) | 1994-09-17 | 1997-12-09 | Boehringer Ingelheim Kg | Neurokinin antagonists |
DE69525355T2 (de) | 1994-09-30 | 2002-09-19 | Novartis Ag | 1-acyl-4-aliphatische aminopiperidin verbindungen |
US5998444A (en) | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
EP0709375B1 (en) | 1994-10-25 | 2005-05-18 | AstraZeneca AB | Therapeutic heterocycles |
US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
US5576317A (en) | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
SK79797A3 (en) | 1994-12-23 | 1997-11-05 | Thomae Gmbh Dr K | Piperazine derivatives, medicaments containing the same, their use and process for preparing the same |
US5700801A (en) | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
NZ321575A (en) * | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
AU7492796A (en) * | 1995-10-31 | 1997-05-22 | Unichema Chemie Bv | Process for the deparaffination of squalane |
TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
DE19608665A1 (de) | 1996-03-06 | 1997-09-11 | Boehringer Ingelheim Kg | Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
US6057323A (en) | 1996-03-08 | 2000-05-02 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US5859012A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0891349A4 (en) | 1996-04-03 | 2001-01-24 | Merck & Co Inc | FARNESYL-PROTEIN TRANSFERASE INHIBITORS |
EP0904080A4 (en) | 1996-04-03 | 2001-08-01 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
WO1997036593A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU3359697A (en) | 1996-07-08 | 1998-02-02 | Yamanouchi Pharmaceutical Co., Ltd. | Bone resorption inhibitors |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
US5929077A (en) | 1996-11-08 | 1999-07-27 | Leftheris; Katerina | Thioproline-containing inhibitors of farnesyl protein transferase |
WO1998024443A1 (en) | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating bipolar disorders |
US5977104A (en) | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
US6114315A (en) | 1996-12-02 | 2000-09-05 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety |
DE19652273A1 (de) * | 1996-12-16 | 1998-06-18 | Basf Ag | Monoolefinische C¶5¶-Mononitrile, Verfahren zu ihrer Herstellung und ihre Verwendung |
AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
WO1999009985A1 (en) | 1997-08-27 | 1999-03-04 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
JP2001524465A (ja) | 1997-11-24 | 2001-12-04 | メルク エンド カムパニー インコーポレーテッド | 細胞接着阻害剤としての置換β−アラニン誘導体 |
AU745425B2 (en) | 1998-01-27 | 2002-03-21 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl factor Xa inhibitors |
GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
AUPR237301A0 (en) * | 2001-01-02 | 2001-01-25 | Fujisawa Pharmaceutical Co., Ltd. | Benzhydryl derivatives |
WO2002000631A2 (en) | 2000-06-29 | 2002-01-03 | Fujisawa Pharmaceutical Co., Ltd. | Benzhydryl derivatives |
DE50110956D1 (de) | 2000-10-12 | 2006-10-19 | Viromics Gmbh | Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen |
GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
US20030022891A1 (en) | 2000-12-01 | 2003-01-30 | Anandan Palani | MCH antagonists and their use in the treatment of obesity |
GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
US20040029865A1 (en) | 2002-05-23 | 2004-02-12 | Acker Brad A. | Bis-arylsulfones |
MY141736A (en) | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
-
2002
- 2002-02-08 GB GBGB0203020.3A patent/GB0203020D0/en not_active Ceased
-
2003
- 2003-02-06 TW TW092102350A patent/TWI291466B/zh not_active IP Right Cessation
- 2003-02-06 AR ARP030100377A patent/AR038818A1/es active IP Right Grant
- 2003-02-06 MY MYPI20030409A patent/MY130411A/en unknown
- 2003-02-10 NZ NZ533785A patent/NZ533785A/en not_active IP Right Cessation
- 2003-02-10 EP EP05077500A patent/EP1666465B1/en not_active Expired - Lifetime
- 2003-02-10 IL IL16276503A patent/IL162765A0/xx unknown
- 2003-02-10 AT AT03702621T patent/ATE308543T1/de active
- 2003-02-10 US US10/502,255 patent/US7189713B2/en not_active Expired - Lifetime
- 2003-02-10 ES ES03702621T patent/ES2250870T3/es not_active Expired - Lifetime
- 2003-02-10 PL PL373532A patent/PL211082B1/pl unknown
- 2003-02-10 DK DK03702621T patent/DK1472256T3/da active
- 2003-02-10 AU AU2003205753A patent/AU2003205753B9/en not_active Expired
- 2003-02-10 JP JP2003566008A patent/JP4488743B2/ja not_active Expired - Lifetime
- 2003-02-10 ES ES05077500T patent/ES2304660T3/es not_active Expired - Lifetime
- 2003-02-10 DE DE60302137T patent/DE60302137T2/de not_active Expired - Lifetime
- 2003-02-10 BR BRPI0307123A patent/BRPI0307123B8/pt not_active IP Right Cessation
- 2003-02-10 CA CA2475619A patent/CA2475619C/en not_active Expired - Lifetime
- 2003-02-10 AT AT05077500T patent/ATE394375T1/de not_active IP Right Cessation
- 2003-02-10 DE DE60320865T patent/DE60320865D1/de not_active Expired - Lifetime
- 2003-02-10 CN CNB03803431XA patent/CN1319973C/zh not_active Expired - Lifetime
- 2003-02-10 RU RU2004126957/04A patent/RU2336276C2/ru active
- 2003-02-10 KR KR1020047012190A patent/KR101011316B1/ko active IP Right Grant
- 2003-02-10 EP EP03702621A patent/EP1472256B1/en not_active Expired - Lifetime
- 2003-02-10 WO PCT/EP2003/001308 patent/WO2003066635A1/en active IP Right Grant
- 2003-02-10 MX MXPA04006791A patent/MXPA04006791A/es active IP Right Grant
-
2004
- 2004-06-18 ZA ZA2004/04842A patent/ZA200404842B/en unknown
- 2004-06-28 IL IL162765A patent/IL162765A/en active IP Right Grant
- 2004-08-02 NO NO20043239A patent/NO329379B1/no not_active IP Right Cessation
- 2004-08-04 IS IS7382A patent/IS2402B/is unknown
- 2004-08-06 CO CO04076757A patent/CO5611152A2/es active IP Right Grant
-
2005
- 2005-04-22 HK HK05103492A patent/HK1072251A1/xx not_active IP Right Cessation
-
2006
- 2006-12-11 US US11/608,853 patent/US7652012B2/en not_active Expired - Lifetime
-
2009
- 2009-12-08 US US12/633,265 patent/US20100152446A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5611152A2 (es) | Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen | |
EA200600364A1 (ru) | Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора | |
AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
PE20021004A1 (es) | Derivados de piperidina como inhibidores de la ccr5 | |
MXPA03011244A (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6. | |
ATE380818T1 (de) | Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose | |
CY1111075T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν τα παραγωγα της 3-αμινο-αζετιδινης, τα νεα παραγωγα τους και η προετοιμασια τους | |
CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
AR025975A1 (es) | Compuestos quimicos. | |
KR20050085991A (en) | Compounds exhibiting thrombopoietin receptor agonism | |
CY1107388T1 (el) | Αγωνιστες αλφα υποδοχεα ενεργοποιουμενου απο πολλαπλασιαστες υπεροξυσωματων | |
NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
MXPA05007341A (es) | Derivados de 2-piperidona como agonistas de prostaglandina. | |
RS51200B (sr) | (imidazol-1-il-metil)-piridazin kao blokator nmda receptora | |
AR035153A1 (es) | Derivados de carboxamidas y cetonas de dihidrobenzodioxina | |
AR245933A1 (es) | Procedimiento para preparar compuestos de 4-(3-hidroxifenil)metil-3-alquil-n-alquilpiperidina y sus sales. | |
NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
CO5550439A2 (es) | Compuestos derivados de arilsulfonil-piperazina que tienen afinidad al receptor 5-ht6 y composiciones farmaceuticas que los contienen | |
AR039988A1 (es) | Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos | |
EA200400748A1 (ru) | Агонисты рецепторов, активируемых пероксисомным пролифератором | |
CO5631442A2 (es) | Nuevos derivados de indolizina 1,2,3 sustituida, inhibidores de los fgfs, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
ATE505462T1 (de) | Neue biologischaktive molekü le | |
HUP9903758A2 (hu) | Benzoxazinon dopamin D4 receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények | |
DK0677042T3 (da) | Selektive ligander af 5HT1D-5HT1B-receptorer, der er afledt af indolpiperazin og er nyttige som lægemidler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |